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The gravity dependence of pharmacodynamics: the integration
of lidocaine into membranes in microgravity
Florian P. M. Kohn1 and Jens Hauslage2
To realize long-term manned space missions, e.g. to Mars, some important questions about pharmacology under conditions of
different gravity will have to be answered to ensure safe usage of pharmaceuticals. Experiments on the International Space Station
showed that the pharmacokinetics of drugs are changed in microgravity. On Earth, it is well known that the incorporation of
substances into cellular membranes depends on membrane ﬂuidity, therefore the ﬁnding that membrane ﬂuidity is gravity
dependent possibly has effects on pharmacodynamics of hydrophobic and amphiphilic substances in microgravity. To validate a
possible effect of gravity on pharmacodynamics, experiments have been carried out to investigate the incorporation of lidocaine
into plain lipid membranes under microgravity conditions. In microgravity, the induced increase in membrane ﬂuidity associated
with lidocaine incorporation is smaller compared to 1g controls. This experiment concerning the gravity dependence of
pharmacodynamics in real microgravity clearly shows that the incorporation of amphipathic drugs into membranes is changed in
microgravity. This might have signiﬁcant impact on the pharmacology of drugs during long-term space missions and has to be
investigated in more detail to be able to assess possible risks.
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INTRODUCTION
Long-lasting manned space missions beyond Earth's orbit, e.g., to
Mars are already planned by space agencies and private
corporations.1 Then humans will have to live in closed environ-
ments under space conditions including microgravity for long
periods without immediate access to medical or pharmacological
support from Earth. To minimize the risk for astronauts, the effects
of relevant drugs under space conditions will have to be
investigated in detail before such manned mission will start. To
assess whether the action of pharmaceuticals is different in
weightlessness compared to Earth, pharmacokinetics (PKs) and
pharmacodynamics (PDs) have to be investigated in more detail to
establish a “space pharmacology”.2,3 According to National
Aeronautics and Space Administration, there is evidence for
inadequate treatment of astronauts during and after a mission.2
Limited data are available for PKs in real weightlessness,
showing that, e.g., the peak concentration of acetaminophen in
the saliva is signiﬁcantly smaller, and the time to reach it is
signiﬁcantly longer compared to Earth.4,5 Unfortunately, no data
exist for PDs in real weightlessness yet. Up to now, only ground-
based experiments (“simulated microgravity”), e.g., from bed rest
studies6 have been performed in 1g. Lidocaine is a local anesthetic
and antiarrhythmic drug included in the International Space
Station (ISS) pharmacy, with potential variability in its PKs due to
metabolism by polymorphic enzymes.7 For this drug, PK changes
have been detected in subjects exposed to 4-day head down tilt
tests.8
On Earth, it is well known that the incorporation of
hydrophobic, amphiphilic, and other similar drugs into mem-
branes depends on membrane ﬂuidity,9 as well as it has been
shown that the incorporation of Alamethicin into lipid monolayers
is surface pressure dependent.10 Furthermore, it was demon-
strated that ligand–receptor interactions are membrane ﬂuidity
dependent, using the nicotinic acetylcholine receptor as a model
system.11
From experiments in clinorotation12 and in real microgravity
and hypergravity13,14 it is known that membrane ﬂuidity itself is
affected by gravity. In microgravity membrane ﬂuidity is increased;
in hypergravity it is decreased.13
Following that the incorporation of hydrophobic (and other)
substances and ligand–receptor interactions depends on mem-
brane ﬂuidity, which in turn is gravity dependent, it can be
concluded that a major part of pharmacological relevant
substances might have changed PDs in microgravity compared
to 1g conditions.
A major class of drugs in the above stated ﬁeld of space
pharmacology are anesthetics, which partially act via membrane
incorporation.15 They are of special interest as a change in their PD
properties could have severe consequences for astronauts.
To assess whether PDs of hydrophobic anesthetics is indeed
affected by gravity, we have used lidocaine as a model substance,
as it is well known that it incorporates into the membrane,16
increasing membrane ﬂuidity.17 The lidocaine-induced ﬂuidization
of membranes was measured by ﬂuorescence polarization (FP) in
1g laboratory conditions and in the microgravity phase during a
sounding rocket ﬂight.
RESULTS
During the microgravity phase of a rocket ﬂight, the incorporation
of 16 mM lidocaine into plain lipid vesicle membranes was
measured by FP as described in the Methods section.
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The data from the microgravity experiment was compared with
the 1g ground reference experiment. In both experiments, 16 mM
lidocaine decreased FP, which means that the ﬂuidity of the
membrane is increased (Fig. 1a). Compared to the 1g reference,
the lidocaine-induced increase in membrane ﬂuidity was smaller
in microgravity.
After the deployment of the parachute (big spike in Fig. 1a), the
FP slightly increased, which means that membrane ﬂuidity was
decreased. This was due to the increased gravity conditions
caused by the reentry into the atmosphere and the deployment of
the parachute (Fig. 1b).
A statistical analysis of the ﬂight and 1g data (Fig. 2) revealed
that the increase in membrane ﬂuidity of asolectin vesicles after
the addition of 16 mM lidocaine is signiﬁcant, but more
importantly, it showed that the increase was signiﬁcantly less in
microgravity compared to 1g. After the onset of gravity,
membrane ﬂuidity was signiﬁcantly decreased compared to
microgravity conditions.
To assess whether lidocaine incorporated into the lipid bilayer,
an additional 1g experiment was executed after the rocket ﬂight.
The vesicle size of the untreated vesicles (not ﬂown but same
vesicle preparation) and of the returned ﬂight sample was
measured by dynamic light scattering (DLS) in the laboratory.
The vesicle size of the returned ﬂight sample (treated with 16 mM
lidocaine during the ﬂight; no additional treatment on Earth)
increased by 10.6%. No time-dependent variation of vesicle size
was observed (Fig. 3).
DISCUSSION
There is experimental evidence that lidocaine affects neuronal
sodium channels directly by binding to the D4-S6 region of the α-
Fig. 1 a Normalized data of the changes in ﬂuorescence polarization (FP) of the microgravity experiment and 1g ground reference. In both
cases, upon addition of 16 mM lidocaine (start of mixing is indicated by arrow; mixing indicated by #2; artifacts caused by moving air bubbles
are marked by #1), FP decreased. A reduced FP indicates a decrease in membrane viscosity or an increase in membrane ﬂuidity. It is visible
that, during microgravity, the increase membrane ﬂuidity is less compared to 1g. The big spike was caused by the high g-load (24.2g) during
the deployment of parachute. One datapoint (second 428) during the deployment was removed as an artifact due to the mechanical shock. b
FP ﬂight data compared to the acceleration proﬁle (vector addition of all three axes x, y, and z). At the end of the ﬂight, the average gravity
increases again, the big spike indicates the opening of the parachute. With onset of gravity, FP slightly increased again. The dotted lines
indicate 0g and 1g
Fig. 2 Statistical analysis of the data from the ﬂight and 1g
experiment. In 1g and in microgravity, 16 mM lidocaine signiﬁcantly
reduced ﬂuorescence polarization (FP), so membrane ﬂuidity is
increased. A comparison between the lidocaine-induced changes of
FP reveals a signiﬁcant smaller decrease in microgravity compared
to 1g. During the reentry phase, FP signiﬁcantly increases again due
to the general gravity dependence of membrane ﬂuidity itself, but it
does not recover to the values before the addition of lidocaine
as this decreases FP. n (from left to right)= 98, 287, 98, 287, 94.
Mean ± SD, Welch–analysis of variance and Games–Howell post hoc
test. *p < .0005
Fig. 3 The change in vesicle size after the addition of 16 mM
lidocaine measured in 1g after the ﬂight. The untreated vesicle
preparation of the rocket mission (not ﬂown) was compared to the
returned ﬂight sample. The mean vesicle radius increased from
72.51 nm before the addition to 80.18 nm afterwards. n= 20.
Boxplot: median, 25 and 75 percentile, whiskers min to max.
Unpaired t test, *p < .0001
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subunit18 and indirectly by modiﬁcation of membrane proper-
ties.19,20 How and to what extent these direct and indirect effects
on ion channels are intertwined for the pharmacological effect is
still under discussion.15,17,21
The direct effect is preferred by many researchers, but it is well
known that ion channel parameters, as the closed-state prob-
ability of the nicotinic acetylcholine receptor, for example, clearly
depend on membrane ﬂuidity.11 Dissolved lidocaine exist in
uncharged and positively charged form,22 the uncharged mole-
cules can diffuse through the membrane and interact with ion
channels directly,17 and the charged lidocaine accumulates in the
hydrophobic part of the lipid membrane.16
By incorporation into the membrane, lidocaine increases
membrane ﬂuidity23,24 and decreases membrane thickness.25 This
can be measured by optical methods as FP,23,26,27 for instance.
However, no absolute values of membrane viscosity can be
obtained with this technique. Nevertheless, it can be used for
relative assessments, e.g., if the ﬂuidity of a sample decreases or
increases or if ≥2 samples differ after treatment with different
lidocaine concentrations.
With these prerequisites, the presented experiment now clearly
shows two things. First, the incorporation of lidocaine into the
membrane increases membrane ﬂuidity (FP is decreased). The
increase in vesicle size after the addition of lidocaine (Fig. 3) is a
strong support that lidocaine molecules really incorporate into the
membrane. More molecules per membrane area could correlate
with an increase in vesicle size.
There are also light scatter experiments indicating that the size
of spheroid cells is increased in microgravity.28 As a lidocaine-
induced decrease in membrane thickness was found,25 an
interesting experiment would be to monitor membrane thickness
in microgravity and hypergravity to evaluate whether this has an
effect on the found general gravity dependence of membrane
ﬂuidity.13
Second and more importantly, the lidocaine-induced increase in
membrane ﬂuidity is gravity dependent. Compared to the 1g
ground control, the increase in ﬂuidity is signiﬁcantly lower in
microgravity.
The demonstrated decrease in membrane ﬂuidity (indicated by
the increase of FP) after the opening of the parachute and the
consequential onset of gravity (Fig. 1a) was expected, as an
increase in gravity should decrease membrane ﬂuidity.13 However,
as there is a lidocaine-induced increase in ﬂuidity, the FP signal
does not fully recover to the measured value before the mixing.
Nevertheless, the general gravity dependence of membrane
ﬂuidity13,14 could be veriﬁed. After the initial 24.2g shock during
parachute deployment, the average g-load was ≥1g. The fast high-
g spikes are not visible in the FP signal, but this is due to the limit
in sampling rate of the system.
From these ﬁndings, it is evident that the PD properties of
lidocaine are different in weightlessness compared to 1g on Earth.
A general gravity dependence of PDs was postulated before,13
and the few experiments on board the ISS focusing on PDs2,4
strongly suggested that PDs should also be affected by gravity,
but it was never investigated up to now.2,3
The presented sounding rocket experiment is an experiment in
real microgravity, which shows that at least the PDs of
hydrophobic and amphiphilic substances indeed is gravity
dependent. Up to now, only experiments under so called
“simulated gravity” (e.g., bed rest studies) exist.6 These experi-
ments can be used to monitor general physiological adaptations
due to changes in, e.g., blood distributions and to investigate
microgravity-related effects, but as they are still executed in 1g
conditions, these types of experiments cannot simulate changes in
membrane ﬂuidity, as this is only changed in real microgravity and
hypergravity.13,29 Therefore, experiments that investigate the
molecular and biophysical principles of membrane interaction
(which are parts of PDs) or use hydrophobic substances have to be
conducted in real microgravity (and hypergravity).
It is known that the properties of the nicotinic acetylcholine
receptor are affected by the biophysical properties of the
membrane.11 Following this, it can be postulated that also
receptor–ligand interactions and other signal cascades should
be affected by gravity14 as most of the receptor proteins are
membrane proteins. From experiments during parabolic ﬂight
missions (generating real microgravity and hypergravity), electro-
physiological data are available, indicating that synaptic transmis-
sion at the motor end plate is also affected.30 Of course, it has to
be investigated in more detail to be able to make a deﬁnitive
statement.
Coming back to the ascertained gravity dependence of
lidocaine PDs, the question arises about the mechanism. One
plausible explanation is that the number of incorporated
molecules is reduced in microgravity due to the general gravity
dependence of membrane ﬂuidity. From Earth-bound experi-
ments, we know that the increase in membrane ﬂuidity depends
on lidocaine concentration. It is increased with rising lidocaine
concentration.31
If the result of this experiment is interpreted to state that less
lidocaine molecules are integrated into the membrane, this would
have a huge impact on space pharmacology. It would mean that
in microgravity the dose of hydrophobic medication (as many
anesthetics are) must be increased. This could—in worst case—
negatively inﬂuence the therapeutic index. The same would be
true for many other drugs as outlined already shortly. Of course,
this has to be veriﬁed with additional experiments not only on the
pharmacokinetic but also on the pharmacodynamic level as well
as with efﬁcacy studies.
Consequently, on long-lasting human space missions, this has
to be taken into account, and sufﬁcient data have to be provided
by setting up a research ﬁeld of space pharmacology,2 which not
only focuses on PKs, where ﬁrst results already have been
delivered,2,32,33 but also has to include PDs as this part was
neglected until now. Data from PK and PD experiments have to be
integrated for better understanding the gravity dependence of
the effect of pharmaceuticals to assess the yet unknown risk for
astronauts. As PD experiments can be conducted with artiﬁcial
systems and cell cultures, these experiments can easily be
repeated with a high number of samples, delivering good
statistical data. Therefore, data from these basic experiments can
support pharmacological experiments with human test subjects in
space, as these experiments usually are conducted with a limited
number of subjects, as the pool of possible test subject is limited
to (mainly) astronauts and volunteers during parabolic ﬂights.
In addition, basic research concerning the biophysical and
molecular principles behind drug–target interactions can be used
to optimize experiment design and analysis of PK experiments
with astronauts. By revealing that the biophysical membrane
properties are affected by gravity13 and that this affects the
incorporation of anesthetics, as shown in this manuscript, the
statement that “the intrinsic ability of a drug to cross a membrane or
to be actively transported is unlikely to be changed in microgravity”32
could be disproved.
A recent review from 2017 revealed that this topic is also of
high interest for jet ﬁghter pilots, as a risk for a difference
disposition of chemicals in the body during high-g maneuvers was
found,34 but—similar to astronauts in weightlessness—the risk
cannot be assessed yet as there is not enough data.
Therefore, to further improve the knowledge about the
interaction of PDs and gravity, a systematic investigation of
membrane interactions and receptor–ligand interactions of
relevant pharmaceuticals and substances is necessary, not only
in microgravity but also in hypergravity.
With an optimized hardware, other, easier accessible research
platforms as parabolic ﬂights or drop towers can be used. The
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used hardware is based on a so called stopped-ﬂow system, which
is regularly used to investigate PD reactions. Depending on the
mixing speed, extremely fast reactions can be measured (in the
range of milliseconds for industrial systems). As it was shown in
the data, the lidocaine-induced change in membrane ﬂuidity is
within the range of seconds and reaches a stable plateau. A fast
system with a faster mixing time could be used in parabolic ﬂights
or drop tower to signiﬁcantly increase the amount of available
data. The number of experiments could also be increased by
performing parallel experiments during the same ﬂight. Then also
the different gravity phases can be investigated in more detail by,
e.g., starting control experiments in 1g to monitor the general
gravity dependence of membrane ﬂuidity throughout the whole
ﬂight. Also, centrifuges can be used to investigate the gravity
dependence of PD in increased gravity.
As vesicle preparations are stable up to several weeks, this type
of experiment could be a good candidate for an automated ISS
experiment, as no cell culture system is needed.
METHODS
Sounding rocket
The experiment was part of the Mapheus program of the German
Aerospace Center (DLR). It was carried out during the Mapheus 6 ﬂight at
Esrange Space Center, Sweden. The rocket was launched on 14 May 2017.
This sounding rocket system was an unguided two-stage rocket and
consisted of a VSB-30 vehicle35 and the scientiﬁc payload on top. During
the ﬂight, a microgravity time of up to 6 min can be achieved with a
microgravity quality of about 10−3–10−4g. The total ﬂight time of Mapheus
6 (from launch to landing of the payload) was 858 s.
Vesicle preparation
The vesicles were made from asolectin (from soybean) as the preparation
of these vesicles is easy and can be established in a laboratory quite fast.
Asolectin is a mixture of unsaturated phospholipids whose main
components are soybean phosphatidylcholine (25%), phosphatidyletha-
nolamine, and phosphatidylinositol.36 It is regularly used in pharmacolo-
gical experiments37 as it is easy to obtain lipid extract of a biological
membrane.
Asolectin was dissolved in chloroform (10mg/ml). Afterwards 1 ml of
this solution was ﬁlled in a round-bottomed ﬂask and the solvent was
removed in a rotary evaporator (300mbar, 1 h) until the lipid remained as a
dry thin ﬁlm. To remove the last residue of solvent, the ﬂask was stored in a
fume hood overnight. After these steps, the lipid ﬁlm was rehydrated with
20ml of phosphate buffered saline (PBS; without Ca2+ and Mg2+) and the
ﬂuorescent dye DPH (1,6-diphenyl-1,3,5-hexatriene; dissolved in dimethyl
sulfoxide (DMSO); end concentration 10 µM) for 1 h at 30 °C. To protect the
dye from light, the ﬂask was completely covered with aluminum foil. The
rehydrated lipid was sonicated (1 h; temperature was kept below 40 °C)
and afterwards centrifuged for (30 min; 3000 × g; room temperature). The
supernatant containing the DPH-doped vesicles was carefully removed
and stored in the fridge in an opaque tube (4 °C). The dyed vesicles were
stable for 14 days. Nevertheless, during the sounding rocket mission, fresh
vesicles were made 24 h before each launch attempt.
Lidocaine solution
Lidocaine hydrochloride was dissolved in PBS (without Ca2+ and Mg2+). A
stock solution of 32mM was used to obtain a ﬁnal concentration of 16mM
after mixing it with the asolectin vesicle solution. This concentration was
determined in previous calibration experiments during the design of the
experiment hardware.
Measurement of membrane ﬂuidity
Changes in membrane ﬂuidity were measured by t-format FP. In short, a
ﬂuorescent probe, DPH in this experiment, was excited by polarized light.
The emission wavelength was measured by two photomultipliers (PMT),
again with polarizers parallel (0°) and perpendicular (90°) to the excitation
light.38 For this experiment, an excitation wavelength of 365 nm was used.
The PMTs recorded emission wavelengths >430 nm.
With these two ﬂuorescence intensities, the rotational speed of the
ﬂuorophore can be measured and this can be used to investigate
membrane ﬂuidity26 and is used to measure the effect of anesthetics such
as lidocaine on membrane ﬂuidity.17,23 The ﬂuorescence signals of the two
PMTs were used to calculate FP in mP.39 As the polarization signals are
sensitive to the cuvette position, the signals of the experiments were
normalized to 100mP to measure the relative changes in ﬂuidity in 1g and
microgravity.
Measurement of vesicle size
The size of the ﬂight sample (before and after addition of 16mM lidocaine
in ﬂight) was measured by DLS after landing of the experiment. Twenty
separate measurements have been made for each condition, with 50 µl of
sample per measurement.
1g reference experiment. The ground reference experiment was per-
formed on the same day as the microgravity experiment in the recovered
experiment hardware. Ambient conditions (pressure and temperature)
were identical to the ﬂight conditions and the same vesicle and asolectin
preparation as used for the rocket mission was used to ensure identical
experiment conditions.
Experiment hardware
The experiment hardware was designed and built to be usable during a
sounding rocket ﬂight, and all required tests (e.g., on g-load and vibrations)
were passed successfully. The hardware consists of three units: (1) the
rocket structure, (2) the late access unit (LAU), and (3) the experiment
module (Fig. 4).
Experiment module
The experiment module contained the ﬂuidic and the optical system. Two
standard syringes (Luer taper; 10 ml) were operated by a motor-driven
syringe pump. They were connected to a coin-shaped quartz glass cuvette
(volume approximately 50 µl) by silicone tubes. The content of both
syringes was mixed in a t-connector that was connected to the inlet port of
the cuvette. To avoid overpressure in the system, a waste container was
connected to the outlet port of the cuvette.
Fluorescence was excited by a ultraviolet light-emitting diode (UV-LED)
with an additional bandpass ﬁlter (365 nm ± 10 nm). By using a long pass
ﬁlter (430 nm), the excitation wavelength was shielded from the two digital
PMTs (Hamamatsu H7155) and thus only emission wavelength was
recorded. FP was measured by using three polarizers: one in front of the
UV-LED, and one in front of each PMT (parallel and perpendicular to the
excitation polarizer). Before each experiment, the experiment unit was
placed inside the pressure-tight chamber of the LAU and was connected to
the power and control system. A basic schematic of the ﬂuidic and the
optical system is shown in Fig. 5.
Fig. 4 Picture of the experiment hardware. (1) Rocket structure, (2)
late access unit (LAU), and (3) experiment module. The experiment
module ﬁts into the pressure chamber of the LAU. The LAU is
integrated into the structure housing shortly before launch
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Late access unit
The LAU had three separate functions. (1) A vacuum-tight chamber
allowed experiments to be carried out under normal pressure (approxi-
mately 1000mbar) during the ﬂight of the rocket. (2) It served as power
supply for the complete experiment. It was powered by accumulators
(12 V, 4800 mAh, NiMH), which were located outside the vacuum chamber.
(3) The electronics to control the experiment and to handle the data were
located on the aluminum base plate in front of vacuum chamber. Via a
vacuum tight plug, data and power lines were connected to the
experiment unit inside the chamber.
The ﬂuorescence signal from each PMT was handled by a dedicated
microcontroller (Arduino Nano 3.0) and was stored on two memory cards.
A third Arduino served as a master controller. It was connected to the main
rocket computer and operated the complete experiment after the proper
start of experiment (SOE) signal was given by the rocket system. It also
synchronized the real-time clock and controlled the subordinate Arduinos
and the experiment module (pumping and switching of the UV-LED).
Ambient data
To be able to execute the 1g reference experiments with the same
temperature proﬁle as given during the rocket ﬂight, temperature was
continuously measured at two locations inside the pressure chamber of
the LAU (directly at the cuvette and near the inner side of the wall) by two
battery-powered data loggers (Arexx BS-30).
Experiment procedures
Three hours before liftoff, two syringes were ﬁlled with (1) 3.5 ml of
asolectin vesicle preparation and (2) 3.5 ml 32mM lidocaine solution. The
silicone tubes and the quartz cuvette were pre-ﬁlled with the same vesicle
preparation to measure the FP baseline signal of the vesicle preparation
without lidocaine after the experiment was started and to remove air
bubbles from the system. After these steps, the experiment unit was
mounted into the pressure chamber of the LAU and it was tightly sealed.
Two hours before the end of the countdown, the LAU was integrated
into the rocket structure, the experiment was connected to rocket service
module, and the experiment was set to standby.
With the onset of microgravity (approximately 70 s after liftoff), the SOE
signal was given and the experiment was switched to active: First, the
baseline FP of the unmodiﬁed DPH-doped asolectin vesicles was measured
for 100 s. Subsequently, the syringe pump was activated and the content
of the two syringes were mixed and the mixture was pumped into the
sample cuvette (18-s pump duration; ﬁnal lidocaine concentration 16mM).
Excess liquid was pumped into the waste syringe. The FP measurement
was continued for additional 425 s to include the gravitational pull after
reentry into the atmosphere and opening of the parachute.
Materials
Asolectin, lidocaine hydrochloride, DPH, DMSO, and chloroform were
purchased from Sigma-Aldrich, Germany. PBS (without Ca2+ and Mg2+)
was purchased from Merck-Biochrom (Berlin, Germany).
The polarizers and optical ﬁlters were purchased from Edmund Optics
Germany. The PMTs are from Hamamatsu Photonics (Hamamatsu, Japan).
The electronics were purchased from R+S components Germany and
Reichelt Elektronik (Sande, Germany). The metal components and the
cuvette were manufactured at the workshops of DLR (Cologne, Germany)
and the University of Hohenheim (Stuttgart, Germany).
Data and statistical analysis
Major goal of this pathﬁnder experiment was to assess the question
whether the incorporation of hydrophobic and amphiphilic substances is
gravity dependent as previously proposed.13
Owing to volume and mass limitations of a sounding rocket mission, the
ﬂight data represent only one replicate. Statistical analysis was performed
using SPSS 25 and GraphPad Prism 6. Data are expressed as mean ± SD of
“n” of the 525 time points of the complete experiment. The mean of each
group was calculated with a minimum of 94 time points (number of time
points: 1g before: 98; 1g+lidocaine: 287; 0g before: 98; 0g lidocaine: 287;
reentry+lidocaine: 94; presented in Fig. 2). Data were tested for normality
using D’Agostino–Pearson omnibus normality test. Normally distributed
data were analyzed for statistical signiﬁcance using two-tailed Student's t
test For non-normally distributed data, statistical signiﬁcance among the
different experiment conditions was assessed by Welch–analysis of
variance and Games–Howell post hoc test.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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